Trevena to Present at the 2016 Wedbush Pacgrow Healthcare Conference
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical-stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the 2016 Wedbush Pacgrow Healthcare Conference on Tuesday, August 16, 2016 at 2:30 p.m. EDT in New York.
To access the live audio webcast of the presentation, please visit the “Investors” section of the company’s website at www.trevena.com. Following the conclusion of the presentation, the webcast will be archived for 30 days.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Oliceridine (TRV130), Trevena’s lead product candidate, is the first pain program granted Breakthrough Therapy designation by the U.S. Food & Drug Administration and is in Phase 3 development for intravenous treatment of moderate to severe post-operative acute pain. In Phase 2b, intravenous oliceridine demonstrated rapid and powerful analgesic efficacy with reduced frequency of opioid-related adverse events including nausea, vomiting, and hypoventilation compared to intravenous morphine, thus offering a promising safety and tolerability profile compared to conventional opioid analgesics while providing powerful pain relief to patients.
Jonathan Violin, Ph.D.
Sr. Director of Investor Relations
Source: Trevena, Inc.
Released August 10, 2016